IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE: UN PROBLEMA TUTTORA APERTO

Translated title of the contribution: The treatment of steroid-resistant nephrotic syndrome: An open problem

B. Damiani, M. Giani, G. Consalvo, A. Carcano, L. Ghio, A. Edefonti

Research output: Contribution to journalArticle

Abstract

The nephrotic syndrome persists unchanged after the initial course of steroid therapy in 15 to 20% of patients. In such cases, the severity of the condition lies essentially in the risk of developing end-stage renal failure. This occurs in one third to one half of the cases. Furthermore, some of these children are at risk for recurrence of their original disease in the transplanted kidney. The course of steroid resistant nephrotic syndrome (SRNS) is usually punctuated by the need for numerous hospitalizations for mobilization of edema and treatment of infection. The treatment of patients with SRNS presents a major problem in the field of pediatric nephrology. Immunosuppressive agents may be efficient in some of steroid-resistant patients, inducing remission of proteinuria and protecting renal function. Unfortunately, all these agents have a low therapeutic index. Thus, in deciding whether, how, and when to use immunomodulating drugs, the nephrologist should be aware of their potential side effects, of the results that may be obtained and of the possible strategies for maximizing their therapeutic index.

Original languageItalian
Pages (from-to)9-15
Number of pages7
JournalPediatria Medica e Chirurgica
Volume17
Issue number1
Publication statusPublished - 1995

Fingerprint

Nephrotic Syndrome
Steroids
Kidney
Therapeutics
Nephrology
Immunosuppressive Agents
Proteinuria
Chronic Kidney Failure
Edema
Hospitalization
Pediatrics
Recurrence
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Damiani, B., Giani, M., Consalvo, G., Carcano, A., Ghio, L., & Edefonti, A. (1995). IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE: UN PROBLEMA TUTTORA APERTO. Pediatria Medica e Chirurgica, 17(1), 9-15.

IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE : UN PROBLEMA TUTTORA APERTO. / Damiani, B.; Giani, M.; Consalvo, G.; Carcano, A.; Ghio, L.; Edefonti, A.

In: Pediatria Medica e Chirurgica, Vol. 17, No. 1, 1995, p. 9-15.

Research output: Contribution to journalArticle

Damiani, B, Giani, M, Consalvo, G, Carcano, A, Ghio, L & Edefonti, A 1995, 'IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE: UN PROBLEMA TUTTORA APERTO', Pediatria Medica e Chirurgica, vol. 17, no. 1, pp. 9-15.
Damiani, B. ; Giani, M. ; Consalvo, G. ; Carcano, A. ; Ghio, L. ; Edefonti, A. / IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE : UN PROBLEMA TUTTORA APERTO. In: Pediatria Medica e Chirurgica. 1995 ; Vol. 17, No. 1. pp. 9-15.
@article{b27590732c7144ac81078ecc0263e999,
title = "IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE: UN PROBLEMA TUTTORA APERTO",
abstract = "The nephrotic syndrome persists unchanged after the initial course of steroid therapy in 15 to 20{\%} of patients. In such cases, the severity of the condition lies essentially in the risk of developing end-stage renal failure. This occurs in one third to one half of the cases. Furthermore, some of these children are at risk for recurrence of their original disease in the transplanted kidney. The course of steroid resistant nephrotic syndrome (SRNS) is usually punctuated by the need for numerous hospitalizations for mobilization of edema and treatment of infection. The treatment of patients with SRNS presents a major problem in the field of pediatric nephrology. Immunosuppressive agents may be efficient in some of steroid-resistant patients, inducing remission of proteinuria and protecting renal function. Unfortunately, all these agents have a low therapeutic index. Thus, in deciding whether, how, and when to use immunomodulating drugs, the nephrologist should be aware of their potential side effects, of the results that may be obtained and of the possible strategies for maximizing their therapeutic index.",
author = "B. Damiani and M. Giani and G. Consalvo and A. Carcano and L. Ghio and A. Edefonti",
year = "1995",
language = "Italian",
volume = "17",
pages = "9--15",
journal = "Pediatria Medica e Chirurgica",
issn = "0391-5387",
publisher = "Vicenza Pediatria Medica E Chirurgica",
number = "1",

}

TY - JOUR

T1 - IL TRATTAMENTO DELLA SINDROME NEFROSICA CORTICORESISTENTE

T2 - UN PROBLEMA TUTTORA APERTO

AU - Damiani, B.

AU - Giani, M.

AU - Consalvo, G.

AU - Carcano, A.

AU - Ghio, L.

AU - Edefonti, A.

PY - 1995

Y1 - 1995

N2 - The nephrotic syndrome persists unchanged after the initial course of steroid therapy in 15 to 20% of patients. In such cases, the severity of the condition lies essentially in the risk of developing end-stage renal failure. This occurs in one third to one half of the cases. Furthermore, some of these children are at risk for recurrence of their original disease in the transplanted kidney. The course of steroid resistant nephrotic syndrome (SRNS) is usually punctuated by the need for numerous hospitalizations for mobilization of edema and treatment of infection. The treatment of patients with SRNS presents a major problem in the field of pediatric nephrology. Immunosuppressive agents may be efficient in some of steroid-resistant patients, inducing remission of proteinuria and protecting renal function. Unfortunately, all these agents have a low therapeutic index. Thus, in deciding whether, how, and when to use immunomodulating drugs, the nephrologist should be aware of their potential side effects, of the results that may be obtained and of the possible strategies for maximizing their therapeutic index.

AB - The nephrotic syndrome persists unchanged after the initial course of steroid therapy in 15 to 20% of patients. In such cases, the severity of the condition lies essentially in the risk of developing end-stage renal failure. This occurs in one third to one half of the cases. Furthermore, some of these children are at risk for recurrence of their original disease in the transplanted kidney. The course of steroid resistant nephrotic syndrome (SRNS) is usually punctuated by the need for numerous hospitalizations for mobilization of edema and treatment of infection. The treatment of patients with SRNS presents a major problem in the field of pediatric nephrology. Immunosuppressive agents may be efficient in some of steroid-resistant patients, inducing remission of proteinuria and protecting renal function. Unfortunately, all these agents have a low therapeutic index. Thus, in deciding whether, how, and when to use immunomodulating drugs, the nephrologist should be aware of their potential side effects, of the results that may be obtained and of the possible strategies for maximizing their therapeutic index.

UR - http://www.scopus.com/inward/record.url?scp=0028936775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028936775&partnerID=8YFLogxK

M3 - Articolo

C2 - 7739938

AN - SCOPUS:0028936775

VL - 17

SP - 9

EP - 15

JO - Pediatria Medica e Chirurgica

JF - Pediatria Medica e Chirurgica

SN - 0391-5387

IS - 1

ER -